We produce institutional quality equity research on small/midÂcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
10
Research Clients
345
Reports published
10k+
Readers in database
ICYMI: FDA granted accelerated approval in #MCL to @LoxoLillyOnc / @LillyPad 's #pirtobrutinib, a BTK inhibitor originally developed by @RedxPharma $REDX
Looking into 2023, @RedxPharma lead assets RXC004 (porcupine inhibitor, Wnt-ligand dep cancers) & RCX007 (ROCK2 inhibitor, IPF) have Phase II data read outs in H2 which should inform next steps & hint at commercial potential. For more on #REDX $REDX see: https://www.trinitydelta.org/companies/redx-pharma/
Global ex-China $1.13bn #fruquintinib licence deal with @TakedaPharma is @hutchmed's 1st major deal under its new strategy. It facilitates & accelerates a broader opportunity for fru beyond #mCRC & beyond China.
For more on $HCM #HCM see: https://www.trinitydelta.org/companies/hutchmed/
4th dose escalation of #AVA6000 Phase Ia successfully completed. Higher dose cohorts to determine MTD (not yet reached) during H123. Biopsy results show materially higher tumour localised doxorubicin concentration than in blood. For more on @avacta #AVCT: https://www.trinitydelta.org/companies/avacta/
AT307 transfer to @hikmapharma triggers licence milestone to @arecor_plc. #AT307 is a ready to use injectable specialty hospital product formulated using its proprietary #Arestat technology. For more on $AREC #AREC see: https://www.trinitydelta.org/companies/arecor-therapeutics/
Wishing you a Merry Christmas & a Happy New Year!🎄
#MerryChristmas #HappyNewYear2023
Please sign up here to be added to our distribution database
; 